T he Infectious Diseases Society of America recently published updated clinical practice guidelines for the management of neutropenic fever. 1 Despite improvements in therapeutic strategies leading to better prognosis for most pediatric patients with malignancy, infection remains a significant cause of morbidity and mortality in those with neutropenia caused by chemotherapy. [2] [3] [4] In neutropenic children with cancer and potentially life-threatening infection, fever may be the only initial manifestation of illness because other signs of systemic disease can be attenuated. Therefore, it is recommended that all children with fever and cancer-related neutropenia be assessed with a complete history and physical examination, undergo appropriate diagnostic studies, and promptly receive empirical antimicrobial therapy.
DEFINITIONS
Fever, generally, is defined as a single oral temperature of at least 38.3°C (101°F), or a temperature of Ն38°C (100.4°F) sustained over 1 hour. Axillary temperatures are discouraged and rectal temperatures are contraindicated in children with chemotherapyinduced febrile neutropenia (FN). Neutropenia is defined as an absolute neutrophil count (ANC) of Ͻ500 cells/mm 3 or an ANC Ͻ1000 cells/mm 3 , which is expected to decrease to Ͻ500 cells/mm 3 in the next 48 hours. Profound neutropenia is defined as an ANC Ͻ100 cells/mm 3 , and prolonged neutropenia is that which lasts Ͼ7 days.
EPIDEMIOLOGY AND ETIOLOGY

Fever occurs in approximately 35%
(range: 10%-60%) of episodes of neutropenia in children, and is most common in patients after hematopoietic stem cell transplantation (HSCT) or aggressive myeloablative treatment for acute leukemia or lymphoma. 5 Documentation of an infectious etiology or focus of infection occurs in only 10% to 45% of febrile episodes. [5] [6] [7] [8] However, infection remains the most common potentially life-threatening complication of cytotoxic chemotherapy. 2, 3 The majority of infections is caused by bacterial pathogens, and bloodstream infection is the most common cause of microbiologically documented FN. Bacteremia, which often is catheter related, occurs in approximately 10% to 20% of febrile neutropenic patients after HSCT or aggressively treated acute leukemia or lymphoma. 5,9 -11 Other frequently involved sites of bacterial infection include the respiratory tract, gastrointestinal tract, and skin and soft tissues.
Enterobacteriaceae are common causes of documented infection in cancerrelated FN due to translocation of organisms from the gastrointestinal tract into the bloodstream. Depending on local epidemiology, some of these pathogens can be multiply drug-resistant (eg, extended-spectrum betalactamase producers). However, although gram-negative pathogens were the predominant cause of infection in febrile neutropenic patients in past decades, gram-positive organisms now are equally, and in some studies more, responsible. 5, 8, 12, 13 The increased incidence of gram-positive pathogens as etiologic agents is the result of increased use of invasive devices, such as central venous catheters, and extensive use of broad-spectrum antimicrobials. 1, 14 Coagulase-negative staphylococci account for the majority of gram-positive organisms isolated, but Staphylococcus aureus (methicillin-resistant and -susceptible) and vancomycin-susceptible and vancomycin-resistant enterococci also occur. 1 In patients with significant mucositis caused by aggressive chemotherapy, viridans streptococci are important and potentially life-threatening pathogens. 14 However, although gram-positive organisms are equally common in patients with FN, gram-negative pathogens, especially Pseudomonas aeruginosa, are associated with greater mortality. 4 Fungi (yeasts and molds) occur in less than 5% of patients with FN but are important causes of morbidity and mortality. 15, 16 These patients often have been treated with prolonged courses of broad-spectrum antimicrobials and typically have neutropenic fever that persists beyond 4 to 7 days or recurs despite antibiotic therapy. 16 Patients with acute myelogenous leukemia (AML) and those who have undergone HSCT are particularly at risk. Candida species are the most common pathogens causing invasive fungal infections (IFI) in febrile neutropenic children. 5, 15 Invasive mold infections (aspergillosis, zygomycosis, fusariosis) are much less common and occur most often in children with profound neutropenia lasting more than 10 days.
CLINICAL AND RISK ASSESSMENT
Assessment of risk for severe infection is crucial in determining the appropriate antimicrobial, route (intravenous vs. oral), venue (inpatient vs. outpatient), and duration of empirical antimicrobial therapy. The type of malignancy and associated chemotherapies, medical comorbidities, relevant history, and presenting signs and symptoms must be considered. In children, studies have sought to stratify risk for serious infection and its complications in febrile neutropenic patients, with varying results. 6, 9, 10, [17] [18] [19] 
High Risk
High-risk patients are those who have an increased risk for severe infection or its sequelae. Studies have found that children are at greater risk of life-threatening infection if they have fever Ն39°C, prolonged neutropenia, recent intensive chemotherapy, underlying diagnosis of AML, bone marrow involvement, relapsed malignancy or second tumor, "sick" clinical appearance (hypotension, respiratory distress, hypoxemia, newonset abdominal pain, neurologic changes), medical comorbidities (eg, renal or hepatic insufficiency), or evidence of focal infection (mucositis, pneumonia, cellulitis, perianal tenderness, presence of a central venous access device). 1, 6, 10, 19 Laboratory abnormalities associated with a high risk of infection include profound neutropenia, a C-reactive protein Ն90 mg/L, platelet count Ͻ20,000 to 50,000 cells/mm 3 ; these factors and an absolute monocyte count Ͻ100 cells/mm 3 also predict a high risk for mortality. 4 ,6,17
Low Risk
Patients are categorized as low risk for infection if they are clinically stable without medical comorbidities and have neutropenia expected to resolve within 7 days. 1, 20 Patients with solid tumors generally have lower risk for infection than those with leukemia or lymphoma. Any patient who does not clearly fulfill criteria for being at low risk of infection should be evaluated and treated according to high-risk guidelines.
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EMPIRIC ANTIBIOTIC THERAPY
High-risk Patients
Febrile neutropenic patients at high risk of infection should be hospitalized and administered broad-spectrum, empirical intravenous antibiotic therapy. 1, 4 Choice of initial antimicrobial therapy should be based on history and physical examination findings as well as local (and the patient's own) epidemiology and antimicrobial susceptibility data. Numerous clinical studies have not established a single best therapeutic regimen for the empiric treatment of patients with FN.
1 Optimal empirical antibiotic therapy should include an agent(s) with bactericidal activity, especially against Pseudomonas aeruginosa, and have a favorable toxicity profile.
Monotherapy with an antipseudomonal beta-lactam agent has been shown to be as effective and as combination therapy in patients who are hemodynamically stable without evidence of skin or soft tissue infection, pneumonia, or concern for catheter-related infection. [21] [22] [23] [24] [25] Current evidence supports the empirical use of piperacillin-tazobactam or cefepime in locations where antimicrobial susceptibility data do not warrant empirical carbapenem (meropenem or imipenem-cilastatin) use. 23, 25, 26 Aztreonam can be used in children with a life-threatening beta-lactam allergy but lacks activity against viridans streptococci (and thus should be used in combination with an agent active against these microbes in patients with severe mucositis). Routine initiation of an aminoglycoside in combination with a beta-lactam agent should be avoided because it offers no survival advantage and is associated with increased toxicity and a higher treatment failure rate. 21 Ceftazidime is no longer recommended for empiric monotherapy in high-risk patients with fever and neutropenia due to its decreasing activity against many gram-negative pathogens. 26 Ceftazidime also offers only weak activity against viridans streptococci.
Despite the prevalence of gram-positive organisms in the etiology of FN, routine use of vancomycin or another agent active against gram-positive pathogens is not recommended as it offers no survival advantage and fails to decrease the length of fever in most patients. 27 However, in communities with a high incidence of infections caused by methicillin-resistant staphylococci and in patients with hemodynamic instability, radiographically documented pneumonia, skin or soft tissue infection, or concern for serious catheter-related infection, addition of vancomycin to the empirical antimicrobial regimen is reasonable. Its addition may not be necessary in patients with mucositis who are receiving monotherapy with piperacillin-tazobactam, cefepime, or a carbapenem, since these drugs provide adequate coverage against viridans streptococci. In patients in whom vancomycin is warranted, if no pathogens have been identified in cultures and no focus of infection is obvious, empirical therapy should be reassessed after 48 to 72 hours. Vancomycin should be discontinued if no obvious indication for ongoing treatment is found.
Low-risk Patients
A large meta-analysis in adults found that oral quinolone therapy alone or in combination with other antibiotics was an acceptable alternative to intravenous therapy in select patients with FN. 28 There was no difference in either mortality or treatment failure rates in febrile neutropenic adults with cancer (other than acute leukemia) who were hemodynamically stable without organ failure, pneumonia, catheter-related infection, or severe soft-tissue infection. In adults, oral levofloxacin is the preferred fluoroquinolone for monotherapy, because it has better activity against gram-positive organisms than ciprofloxacin.
1 Selected low-risk adult patients, who can be followed closely and in whom prompt access to appropriate medical care is ensured, are candidates for outpatient management of FN with oral antibiotic therapy.
Few studies exist in low-risk children with FN to support initial therapy with an oral agent. 29 Considerable variation in practice exists, but initial inpatient or emergency center management of low-risk patients with FN remains routine in many (but not all) centers. A prospective, randomized, singleinstitution trial of 135 children with low-risk FN, most of whom had leukemia, found excellent clinical outcomes and no difference in treatment failure in children who received oral ciprofloxacin versus intravenous ceftriaxone after a single dose of ceftriaxone and amikacin. 30 In the United States, the use of oral fluoroquinolones empirically in low-risk children with FN and cancer is an off-label use.
A recent study from Switzerland of more than 400 episodes of FN among 206 children reported that 8% of bacteremic episodes were identified only after inpatient
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The Pediatric Infectious Disease Journal • Volume 30, Number 10, October 2011 reassessment at 8 to 24 hours; prediction of bacteremia at the reassessment was better than that at presentation of FN. 11 Hakim et al 19 also highlighted the importance of both the initial clinical assessment and 24 hours of close observation in detecting invasive bacterial infection or a clinical complication in low-risk patients. Often, outpatient management of low-risk children with FN is not feasible because of nonmedical barriers, including transportation issues, language barriers, and lack of parent or physician comfort with care outside of the hospital.
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Duration of Antibiotic Therapy
In a child with a documented focus of infection, the duration of therapy is determined by the site of the infection, the clinical response (including resolution of fever) and the pathogen identified. In general, directed antimicrobial therapy should continue at least until the ANC exceeds 500 cells/mm 3 (bone marrow recovery). When the source of the fever remains unknown, the initial choice of antibiotic therapy should be continued until bone marrow production of granulocytes has recovered.
ANTIFUNGAL THERAPY
High-risk Patients
Initiation of antifungal therapy is recommended in high-risk children with chemotherapy-induced neutropenia when fever persists or recurs at 4 to 7 days.
1 Candida (yeast) and Aspergillus (mold) are the most common pathogens causing IFI, although infection due to mold is most common in patients with profound neutropenia and fever lasting beyond 7 to 10 days. 1, 32 Limited data are available comparing antifungal agents in children with suspected IFI. 33, 34 Important considerations in choosing an antifungal agent include type of antifungal prophylaxis (if any) and local epidemiology of Candida isolates. In patients who have not been given fluconazole prophylaxis and lack risk factors for mold infection, fluconazole may be an appropriate empiric therapy. For those in whom there is concern for IFI caused by fluconazole-resistant Candida species (Candida krusei or Candida glabrata) or mold, amphotericin B, echinocandins (eg, caspofungin), and newer azoles (voriconazole or posaconazole) are options. One should consider choosing an empirical antifungal (preferably intravenous) agent that is in a different class from that used for prophylaxis.
Children and adults are less likely to develop nephrotoxicity or infusion-related effects with liposomal amphotericin B than other amphotericin formulations. 32, 34 One randomized, multicenter study of 82 children aged 2 to 17 years with persistent fever and neutropenia compared empiric caspofungin and liposomal amphotericin B and found no difference in safety, tolerability, and efficacy between the treatment groups. 33 The use of 2 antifungals from different classes of moldactive agents (combination therapy) can be considered in patients with documented IFI who are clinically unstable or worsening, but this approach is controversial and no supportive efficacy data exist from well-controlled trials.
Low-risk Patients
Empirical antifungal therapy is not recommended for low-risk patients with chemotherapy-induced FN.
Duration of Antifungal Therapy
The duration of antifungal therapy in a child with a documented focus of infection is determined by the site of the infection, the clinical response (including resolution of fever and results of imaging studies and serum fungal assays) and the pathogen identified. In general, directed antifungal therapy should continue at least until bone marrow recovery. When the source of the fever is unknown, antifungal therapy should continue until resolution of fever and bone marrow recovery. Longer durations of therapy may be warranted when there is evidence of persisting fungal infection after marrow recovery and neutropenia is likely to recur soon due to the next chemotherapy cycle.
ANTIMICROBIAL PROPHYLAXIS Antibiotics
The Infectious Diseases Society of America recommends considering fluoroquinolone prophylaxis for high-risk afebrile adult patients with anticipated prolonged and profound neutropenia, although some controversy remains regarding precisely which patients are most appropriate for prophylaxis. 1 However, no clear recommendation is found for children since high-quality clinical trials assessing the safety and efficacy of prophylaxis are lacking, and concern regarding increases in infections due to fluoroquinolone-resistant pathogens exists. In general, antibiotic prophylaxis (with fluoroquinolones) in children is considered only in very high-risk situations (eg, allogeneic HSCT, aggressive myeloablative therapy for leukemia).
Antifungals
Antifungal prophylaxis (eg, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin) against Candida species is recommended in those patients most at risk for IFI, such as allogeneic HSCT recipients and patients undergoing intensive chemotherapy for acute leukemia. Prophylaxis against Aspergillus is recommended in patients with a prior history of IFI, neutropenia anticipated to last beyond 2 weeks, or prolonged neutropenia prior to HSCT. 35 Posaconazole prophylaxis is recommended specifically for patients aged more than 12 years undergoing induction chemotherapy for AML or intensive chemotherapy for myelodysplastic syndrome.
1 Posaconazole absorption is variable, and drug interactions with chemotherapeutic agents are a potential concern. 1 The duration of antifungal prophylaxis is uncertain; however, patients with acute leukemia generally are treated until myeloid reconstitution, and HSCT recipients through day 75 posttransplantation or cessation of immunosuppression.
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Antivirals
Patients who are seropositive for herpes simplex virus undergoing induction therapy for leukemia or allogeneic HSCT warrant acyclovir prophylaxis. Prophylaxis generally is continued until bone marrow recovery. However, in patients with recurrent herpes simplex virus infections or graftversus-host disease, prolonged antiviral prophylaxis may be necessary. All patients with cancer and their household contacts should be immunized annually with influenza vaccine. Further, neutropenic patients exposed to influenza should receive prophylaxis with a neuraminidase inhibitor (eg, zanamivir, oseltamivir). Neutropenia is not a risk factor for reactivation of other herpes viruses such as cytomegalovirus and human herpes virus 6. No other antiviral prophylaxis regimens have been proven effective for patients with chemotherapy-induced FN.
SUMMARY
Children with fever and chemotherapyinduced or cancer-associated neutropenia should be assessed with complete history and physical examinations, undergo appropriate diagnostic studies, and promptly receive broad-spectrum empirical antimicrobial therapy. Assessment of risk for severe infection is crucial in determining the appropriate antimicrobial, route, venue, and duration of empirical antimicrobial therapy and need for prophylactic antimicrobial agents.
